Belite Bio Adr Stock Performance
| BLTE Stock | USD 63.26 4.18 6.20% |
On a scale of 0 to 100, Belite Bio holds a performance score of 9. The firm shows a Beta (market volatility) of 0.68, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Belite Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Belite Bio is expected to be smaller as well. Please check Belite Bio's total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power , to make a quick decision on whether Belite Bio's price patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Belite Bio ADR are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Belite Bio exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (6.20) | Five Day Return (21.42) | Year To Date Return 47.94 | Ten Year Return 497.36 | All Time Return 497.36 |
1 | Belite Bio Announces First Patient Dosed in Phase 23 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease | 09/10/2024 |
2 | Heres Why Were Not At All Concerned With Belite Bios Cash Burn Situation | 09/24/2024 |
3 | Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting | 10/14/2024 |
4 | Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results | 11/05/2024 |
5 | Belite Bio Reports Q3 2024 Results Progress in Stargardt and Geographic Atrophy Trials | 11/12/2024 |
6 | Belite Bio stock soars to all-time high of 84.2 amid robust gains - Investing.com Australia | 11/14/2024 |
7 | Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007 | 11/27/2024 |
| Begin Period Cash Flow | 42.1 M |
Belite |
Belite Bio Relative Risk vs. Return Landscape
If you would invest 4,839 in Belite Bio ADR on September 1, 2024 and sell it today you would earn a total of 1,487 from holding Belite Bio ADR or generate 30.73% return on investment over 90 days. Belite Bio ADR is currently generating 0.5139% in daily expected returns and assumes 4.1934% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Belite, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Belite Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Belite Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Belite Bio ADR, and traders can use it to determine the average amount a Belite Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1225
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BLTE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.19 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.51 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Belite Bio is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Belite Bio by adding it to a well-diversified portfolio.
Belite Bio Fundamentals Growth
Belite Stock prices reflect investors' perceptions of the future prospects and financial health of Belite Bio, and Belite Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Belite Stock performance.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 2 B | ||||
| Shares Outstanding | 30.88 M | ||||
| Price To Book | 18.56 X | ||||
| EBITDA | (31.53 M) | ||||
| Net Income | (31.63 M) | ||||
| Cash And Equivalents | 48.7 M | ||||
| Cash Per Share | 1.96 X | ||||
| Total Debt | 886 K | ||||
| Current Ratio | 35.01 X | ||||
| Book Value Per Share | 3.66 X | ||||
| Cash Flow From Operations | (29.84 M) | ||||
| Earnings Per Share | (1.10) X | ||||
| Market Capitalization | 2.08 B | ||||
| Total Asset | 94.64 M | ||||
| Retained Earnings | (71.5 M) | ||||
| Working Capital | 86.31 M | ||||
About Belite Bio Performance
By analyzing Belite Bio's fundamental ratios, stakeholders can gain valuable insights into Belite Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Belite Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Belite Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (31.52) | (33.10) | |
| Return On Tangible Assets | (0.35) | (0.36) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | (0.35) | (0.33) |
Things to note about Belite Bio ADR performance evaluation
Checking the ongoing alerts about Belite Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Belite Bio ADR help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Belite Bio ADR appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (31.63 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Belite Bio ADR currently holds about 48.7 M in cash with (29.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.96. | |
| Belite Bio ADR has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007 |
- Analyzing Belite Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Belite Bio's stock is overvalued or undervalued compared to its peers.
- Examining Belite Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Belite Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Belite Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Belite Bio's stock. These opinions can provide insight into Belite Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Belite Stock analysis
When running Belite Bio's price analysis, check to measure Belite Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Belite Bio is operating at the current time. Most of Belite Bio's value examination focuses on studying past and present price action to predict the probability of Belite Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Belite Bio's price. Additionally, you may evaluate how the addition of Belite Bio to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |